Camp4 Therapeutics CORP 10-Q quarterly reports

CAMP4 Therapeutics Corporation filed its Q2 2026 Form 10-Q, detailing ongoing R&D efforts, a significant net loss, and progress towards initiating its Phase 1/2 clinical trial for CMP-002.

CAMP4 Therapeutics reports increased collaboration revenue in Q1 2026, but a wider net loss driven by derivative liability revaluation.

CAMP4 Therapeutics reported increased cash reserves and collaboration revenue in its Q3 2025 filing, driven by a recent private placement, while pausing new investment in its UCD program.

CAMP4 Therapeutics Corporation reported a net loss of $12.6 million for Q2 2025, with cash reserves projected to last only into Q2 2026, raising substantial doubt about its ability to continue as a going concern.

CAMP4 Therapeutics reports a net loss of $12.4 million for Q1 2025 and anticipates current cash reserves will fund operations into Q2 2026.

CAMP4 Therapeutics Corporation reported its financial results for the third quarter of 2024, highlighting ongoing clinical development efforts and financial updates.